CMPX — Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 35
- Website: https://www.compasstherapeutics.com
Latest SEC filings for CMPX
- 8-K — 2026-09-22
- SCHEDULE 13G — 2026-08-07
- 8-K — 2026-08-06
- 10-Q — 2026-08-06
- 8-K — 2026-07-01
- 8-K — 2026-06-23
- 8-K — 2026-06-11
- 10-Q — 2026-05-05
- 8-K — 2026-05-05
- ARS — 2026-04-29
Latest CMPX news
- — Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 (GlobeNewswire Inc.)
Educational tool only — not investment advice.